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INTRODUCTION 
Systematic reviews fulfil a vital role in modern medicine.(1) However, the results of systematic 
reviews are only as valid as the studies they include.(2) Pooling flawed, or biased, studies can 
compromise the credibility of systematic review findings. Bias is a systematic deviation in the true 
results of a research study that can manifest due to limitations in study design, conduct, or analysis.(3) 
 
The results of sport and exercise medicine (SEM) research, like results in other fields, are vulnerable 
to bias.(4) It is important that systematic review authors assess for bias in a way that enables a 
judgement about whether a review outcome is at risk of bias due to methodological limitations in 
included studies. This two-part education primer focuses on how systematic review authors can 
perform and interpret risk of bias assessments to avoid misleading systematic review conclusions. In 
this editorial, we introduce the concept of risk of bias, and the principles of assessing risk of bias.  
 
BIAS: THE BASICS 
Different biases have effects that vary in direction and magnitude.(3,5) It is challenging to precisely 
determine how bias over- or under-estimates an individual study’s true findings. In fact, bias does not 
always result in distorted study findings and one can never be certain that bias is present when a study 
has methodological limitations. However, methodological limitations in study design, conduct, or 
analysis can be consistently associated with inflated research findings.(5) Due to this uncertainty, 
study outcomes are considered to be at risk of bias rather than ‘biased’. 
 
Studies with ‘some concerns’ or ‘high’ risk of bias in design, conduct, analysis, or reporting are at 
greater risk of inflated findings compared to studies at ‘low’ risk of bias, negatively affecting the 
probability that study findings accurately reflect reality.(5,6) Assessing the risk of bias of study 
outcomes that are included in a systematic review allows readers to interpret the credibility of review 
findings. 
 
DON’T CONFUSE RISK OF BIAS WITH STUDY QUALITY  
Risk of bias is a clearly-defined term and refers to the perceived risk that the results of a research 
study deviate from the truth.(3) Unfortunately, risk of bias is often conflated with study quality, 
despite being distinct constructs (Table 1). 
 
Study quality is a vague and multi-dimensional term that loosely indicates how closely a research 
study is conducted to the highest possible methodological standards.(3) Quality refers to several areas 
of study methodology, with each area having different implications for how one should interpret a 
study’s methodological rigor (Table 1).(7) A risk of bias assessment should not be replaced by an 
assessment of study quality.(8) When critically appraising a research study, assessors should prioritise 
how closely a study’s findings approximate the truth (i.e., risk of bias) over how well the study was 
conducted (i.e., quality) (Table 1). 
 
USE DOMAIN-BASED RISK OF BIAS ASSESMSENT TOOLS INSTEAD OF QUALITY 
SCALES AND CHECKLISTS 
A plethora of assessment tools are available to critically appraise a research study.(9) However, not all 
of these tools are appropriate to assess risk of bias. This can confuse researchers about which tool is 
the most suitable tool to use. Broadly, three types of tools exist to assist researchers and readers in 
critically appraising a study: (1) quality scales, (2) quality checklists, and (3) domain-based risk of 
bias tools.(3) We explain why domain-based risk of bias tools are preferred over quality scales and 
checklists.  
 
Quality scales and quality checklists vary substantially in content, complexity, and rating criteria, and 
often include items that are not related to bias.(10) Quality scales assign numeric values to scale items 
and combine information about several methodological features in a study to produce a summary 
score.(9) For example, the PEDro scale includes items related to internal validity (e.g., random 
allocation) and reporting (e.g., clear description of participant eligibility criteria). A lack of a random 
allocation undermines the credibility of a study’s findings (i.e., there is a ‘high risk’ of selection bias). 
Unclear eligibility criteria challenge a study’s reproducibility and make it difficult to judge to whom 
the study findings are applicable (i.e., external validity). In the presence of good reporting but poor 
methodological conduct, quality assessment may overestimate the credibility of study findings.(11,12)  
 
Quality checklists contain items that relate to study quality without assigning numeric values or 
producing a summary score.(3,9) For example, the Quality Assessment Tool for Observational Cohort 
and Cross-Sectional Studies contains items relating to reporting, sample size, statistical power, 
precision, external validity, and internal validity (bias); requiring “yes”, “no”, or “other” responses to 
each item. Such quality checklist items do not solely address risk of bias and are not intended to be 
summed to produce one numeric score. However, review authors frequently modify quality checklists 
(by assigning arbitrary numeric values) to generate summary scores and summarise study quality. 
Summary scores do not inform the reader which biases might be present.(12) 
 
Using quality scales and quality checklists is discouraged because different scales tend to generate 
conflicting conclusions when applied to the same studies.(11) Quality scales are also prone to 
misleading conclusions when relying on cut-off thresholds that arbitrarily categorize study quality as 
‘high’, ‘moderate’, or ‘low’.(13) 
 
Domain-based risk of bias assessment tools are currently the commonly accepted and preferred 
method to judge the credibility of study findings.(3) Domain-based tools evaluate study limitations in 
specific domains that represent different biases (e.g., bias arising from the randomization 
process).(3,5) Domain-based tools overcome many shortcomings of quality scales, as they evaluate 
individual components that relate to study design, conduct, and analysis rather than a single summary 
score.(14) Several study design-specific, domain-based risk of bias assessment tools have been 
developed.(15–20) The Cochrane Risk of Bias tool 2 (RoB2) is a rigorously developed, domain-based 
risk of bias assessment tool that assesses the limitations of randomised controlled trials across five 
bias domains.(21) Each bias domain possesses strong empirical evidence that study limitations may 
distort study findings.(5) 
 RISK OF BIAS ASSESSMENT METHOD 
Risk of bias assessments should be performed for each outcome of interest rather than as one general 
assessment for each study.(22) If a study includes multiple outcomes and time-points, separate risk of 
bias assessments should be undertaken for each included outcome (Table 2). Bias can impact review 
outcomes differently,(5,22) underscoring the need for separate risk of bias assessments when multiple 
outcomes are reported upon (Table 2). Cochrane recommends two approaches to risk of bias 
assessments.(3) Both approaches involve a domain-based risk of bias assessment of separate 
outcomes, assessing: 
(1) Individual review outcomes, in each individual study, based on individual risk of bias domains. 
(2) Individual review outcomes, across included studies (i.e., meta-analysis level), based on individual 
risk of bias domains. 
In part two, we demonstrate both risk of bias assessment methods. 
 
SUMMARY 
In this editorial, we introduced risk of bias as the perceived risk that the results of a research study 
may under- or over-estimate the truth. Systematic review authors should perform a domain-based risk 
of bias assessment that reflects risk of bias instead of assessing study quality. If a research study 
reports upon multiple outcome measures, separate risk of bias assessments should be performed for 
each outcome measure.  
In part 2 of this risk of bias education primer, we: 
1. Evaluate the prevalence and methods of risk of bias assessments in systematic reviews 
published in BJSM.  
2. Perform a risk of bias assessment on a sample of RCTs in a systematic review. 
3. Illustrate the impact that different critical assessment tools have on risk of bias assessment 
findings, and ultimately, systematic review findings. 
4. Provide recommendations for systematic review authors undertaking risk of bias assessments. 
 
Table 1 – Key terms relating to risk of bias and critical appraisal 
Key terms Explanation 
Risk of bias Bias is a systematic deviation from the truth in the results of a research study. Bias may occur due to limitations in 
study design, conduct, analysis, or reporting.(3) Bias is associated with under-estimated or over-estimated study 
findings. Multiple sources of bias exist, and different biases can vary in direction and magnitude. Assessing bias 
can never conclusively determine whether a study’s findings under-estimate or over-estimate a true result because 
study findings can be unbiased despite methodological limitations. Therefore, risk of bias, rather than bias, is 
assessed to determine the likelihood that bias is present. Risk of bias is synonymous with the term internal 
validity. 
Study quality Study quality is the extent to which a study is conducted to the highest methodological standards possible. Study 
quality evaluates multiple constructs of study methodology including reporting completeness, ethical approval, 
statistical power, precision, and internal and external validity.(7,9) 
Risk of bias & 
study quality 
  
The terms ‘risk of bias’ and ‘study quality’ are often used interchangeably. However, both terms are distinct 
constructs. Discrepancies between study quality and risk of bias are highlighted when performing a risk of bias 
assessment. Blinding participants in RCTs can be challenging and often impossible in SEM research (e.g., 
randomising professional football players to receive a Nordic hamstring exercise programme, or not). A RCT that 
cannot blind participants might be considered high-quality because it may be the only way for trial investigators 
to conduct such a RCT. However, risk of bias targets the extent to which study findings should be believed, 
irrespective of researchers’ (in)ability to prevent methodological shortcomings that may affect study findings. 
Because participants were not blinded, the trial outcome is at ‘high’ risk of bias – this fact is inescapable.(3) 
Reporting 
quality 
Reporting quality refers to the extent to which an original research article provides complete and transparent 
information about the design, conduct, analysis, and results of a study. Complete reporting facilitates a 
comprehensive assessment of a study’s internal and external validity, and study design-specific reporting 
guidelines exist to guide systematic review reporting.(23) Good- or poor-quality reporting in a study does not 
imply that the study’s outcomes are at ‘low’ or ‘high’ risk of bias, respectively.(24) For example, there is a 
difference between reporting whether a methodological procedure, such as randomization, was performed, and 
whether it was performed appropriately to sufficiently minimize risk of bias (e.g., by using simple randomization 
from a computer-generated random numbers table, with an equal allocation ratio).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – Concepts in the assessment of risk of bias 
Concept Explanation 
Domain-based risk 
of bias assessments 
  
Domain-based risk of bias assessments identify specific study limitations that can introduce different biases 
(e.g., bias arising from the randomization process or bias due to deviation from intended interventions). 
Specific risk of bias domains provide insight into why a study outcome might be distorted, and by how much. 
For example, RCTs at ‘high’ risk of bias due to inadequate allocation concealment will be associated, on 
average, with over-estimated trial outcomes in favour of the experimental group compared to RCTs at ‘low’ 
risk of bias.(5)  
Assessing review  
outcomes separately. 
Study limitations that inform judgements of ‘some concerns’ or ‘high’ risk of bias can distort outcome 
measures differently.(5) For example, pain is more likely to be over-estimated when a patient is aware of their 
allocation to a specific intervention group (due to lack of patient blinding) than if they were not aware of their 
group allocation.(5,22) Conversely, a patient’s awareness of their allocation to an intervention group is less 
likely to influence an outcome such as re-injury.(5,22) Systematic review authors should perform separate risk 
of bias assessments for each outcome rather than assessing all review outcomes at once with one, general risk 
of bias assessment. A domain-based risk of bias assessment for separate outcomes evaluates the judgements of 
each risk of bias domain for separate review outcome types. 
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